research The antiandrogenic effect of finasteride against a mutant androgen receptor
Finasteride may improve prostate cancer treatment outcomes.
Search
for
Sort by
Research
270-300 / 1000+ results research The effect of the combined drug Yuperio with bisoprolol on the dynamics of the heart with dilation of the left chambers, the development of which is due to non-compactness of the myocardium of the left ventricle
Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Inhibition of Human Steroid 5β-Reductase (AKR1D1) by Finasteride and Structure of the Enzyme-Inhibitor Complex
Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.
research Finasteride, A Steroid 5α-Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine
Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
research New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research SRD5A2 and emerging therapies in androgen-driven disorders
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research Associations between semen quality and lower urinary tract symptoms in ageing male
The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Comparison of the effects of the K+-channel openers cromakalim and minoxidil sulphate on vascular smooth muscle
Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.
research In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions
Finasteride affects UGT1A4 enzyme, but not enough to cause issues when combined with other drugs.
research A New Era of 5α-Reductase Inhibitors for Androgenetic Alopecia
New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
research 복분자 미숙과 추출물이 전립선암 세포주와 전립선비대 백서모델에 미치는 영향
Unripe Rubus occidentalis extracts may help treat benign prostatic hyperplasia.
research IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
IsoPSA test works accurately even if patients take certain prostate medications.
research MP24-09 MEN WITH AN IMPROVEMENT IN URINARY SYMPTOMS HAVE A LOWER RISK OF MORTALITY
Men with better urinary symptoms have a lower risk of death.
research Effects of PNU157706, a Dual 5α-Reductase Inhibitor, on Rat Epididymal Sperm Maturation and Fertility1
PNU157706 reduced rat sperm movement and fertility without affecting offspring health.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Antiandrogens
Antiandrogens block male hormones and are not safe during pregnancy.
research The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Antiandrogens: Clinical applications
Antiandrogens help treat hormone-related conditions in both men and women.
research Analysis of Cost-effectiveness of 4 Kinds of Projects for Drug Therapy in the Treatment of BPH
Using tamsulosin with finasteride is the most effective and reduces surgery risk for BPH.
research Cyclohex-1-ene Carboxylic Acids: Synthesis and Biological Evaluation of Novel Inhibitors of Human 5α Reductase
Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
research The Emerging Structural Pharmacology of ATP-Sensitive Potassium Channels
KATP channels are important for energy balance and are targeted by drugs for diabetes, hypoglycemia, hypertension, and hair loss.
research Doxazosin and finasteride alone or in combination: the PREDICT study
Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
research Five-alpha-reductase Inhibitors for prostate cancer prevention.
5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.